Shanxi PUDE Pharmaceutical Co., Ltd.

This product is a semi-synthetic β-lactamase inhibitor, which has strong antibacterial activity against Neisseria gonorrhoeae, Neisseria meningitidis and Acinetobacter calcoaceticus, and has poor effects on other bacteria, but has strong irreversible competitive inhibition of β-lactamase produced by Staphylococcus aureus and most Gram-negative bacteria. When used in combination with penicillins and cephalosporins, it can reduce the MIC of Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, Bacteroides fragilis, etc., which are resistant to the first two types of antibiotics due to enzyme production, to within the sensitive range. This product has a strong affinity for PBP1 of Bacillus mirabilis and PBP2 of Acinetobacter calcoaceticus.

It is a cell cycle-specific antitumor drug that inhibits the polymerization of intracellular tubulin, prevents the formation of spindles in the mitosis of proliferating cells, and stops cell division at the metaphase of mitosis. This product has a broad antitumor spectrum for transplanted animal tumors and has no complete cross-resistance with vinblastine and vincristine.

It is a cell cycle-specific antitumor drug that inhibits the polymerization of intracellular tubulin, prevents the formation of spindles in the mitosis of proliferating cells, and stops cell division at the metaphase of mitosis. This product has a broad antitumor spectrum for transplanted animal tumors and has no complete cross-resistance with vinblastine and vincristine.

Aminoglycoside antibiotics, with an antibacterial spectrum similar to kanamycin but with weaker antibacterial activity, have good antibacterial activity against Escherichia coli, Klebsiella, Proteus and other Enterobacteriaceae, also have good effects on some Staphylococci (methicillin-sensitive strains), Neisseria gonorrhoeae, and Neisseria meningitidis, have weak effects on Mycobacterium tuberculosis and Streptococcus, and have no effect on Pseudomonas aeruginosa and anaerobic bacteria. Mainly binds to the 30S subunit of bacterial ribosomes, inhibiting bacterial protein synthesis. Less toxic than kanamycin.

Aminoglycoside antibiotics, the antibacterial spectrum is similar to that of kanamycin but weaker, it has good antibacterial activity against Escherichia coli, Klebsiella, Proteus and other Enterobacteriaceae, and also has good effects on some Staphylococci (methicillin-sensitive strains), Neisseria gonorrhoeae, and Neisseria meningitidis, has a weak effect on Mycobacterium tuberculosis and Streptococcus, and has no effect on Pseudomonas aeruginosa and anaerobic bacteria. Bacteria have cross-resistance to this product and kanamycin. It mainly binds to the 30S subunit of the bacterial ribosome and inhibits bacterial protein synthesis. The toxicity is lower than that of kanamycin.